Medicines Co. Said to Weigh Strategic Options for European Unit

Medicines Co. is weighing options including a sale for its European business as the drug developer seeks to benefit from the boom in health-care deals, according to people familiar with the matter.

The company is working with financial advisers from Rothschild on the review, which may lead to a sale, licensing agreement or partnership for its treatments in Europe, the people said, asking not to be identified because the process is private. While no agreement is imminent, work on the review is advanced, the people said.